The saga is remarkable in several ways, not least of which is that although both the drugmakers and regulators were exploringunknown territory, the development of the drug and its regulatory review progressed smoothly and rapidly.
The robots create a 2D map of the area they are exploring, but when they come to an unknown area, they check back through this information to see if it seems similar to any areas that have already explored.